Search

Displaying results 1891 - 1900 of 7452 in total
  1. Drug

    Retapamulin

    go.drugbank.com/drugs/DB01256
    Approved

    Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.

    Categories: Antibiotics for Topical Use
  2. Drug

    Iomeprol

    go.drugbank.com/drugs/DB11705
    ApprovedInvestigational

    Iomeprol is a tri-iodinated, non-ionic radiographic contrast agent for intraarterial or intravenous use.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    The FDA recommends vaccination with Yellow Fever Vaccine for persons living in or travelling to endemic areas and for laboratory personnel who handle virulent yellow fever virus or concentrated preparations … Although there is supportive treatment available for managing Yellow Fever, there are currently no antivirals developed to specifically treat Yellow Fever.

    Categories: Antiinfectives for Systemic Use
  4. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints. … It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions.

  5. Drug

    Sulfadiazine

    go.drugbank.com/drugs/DB00359
    ApprovedInvestigationalVet approved

    One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. … It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.

  7. Drug

    Levallorphan

    go.drugbank.com/drugs/DB00504
    Approved

    It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants

    Categories: Heterocyclic Compounds with 4 or More Rings
  8. Drug

    Rexin G

    go.drugbank.com/drugs/DB16450
    Investigational

    It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry. … Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene.

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Cinchocaine

    go.drugbank.com/drugs/DB00527
    ApprovedVet approved

    A local anesthetic of the amide type now generally used for surface anesthesia.

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anesthetics for Topical Use
  10. Drug

    Ceftobiprole

    go.drugbank.com/drugs/DB04918
    ApprovedWithdrawn

    for skin and skin structure infections and bacteremia in April 2024. … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European